Recruiting

Precise Exercise Regimen

Sponsor:

Dana-Farber Cancer Institute

Code:

NCT07412041

Conditions

Stage II Lung Cancer

Lung Cancer

Non-small Cell Lung Cancer

NSCLC

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

PERCC

Study Details

Brief summary:

The purpose of this study is to test the feasibility of the Precise Exercise Regimen for Cancer Care (PERCC) exercise program in participants with stage II-III primary lung cancer.

Conditions

Stage II Lung Cancer

Lung Cancer

Non-small Cell Lung Cancer

NSCLC

Study ID

NCT07412041

Start date

Jan 22, 2026

Status verified date

Feb, 2026

Completion date

Mar 30, 2028

Anticipated

Primary completion date

Mar 30, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age ≥18 years at time of diagnosis; due to the rarity of the disease in those <18 years, this age bracket will not be included.
  • Histologically diagnosed with stage II or III non-small cell lung cancer (NSCLC) and has not started lung cancer treatment.
  • Patient's treatment plan is to receive neoadjuvant therapy (defined as chemotherapy, chemotherapy and immunotherapy, or chemotherapy and radiation therapy) followed by surgical treatment. Patients will be enrolled at least three weeks prior to receiving their first neoadjuvant treatment.
  • Ability to follow directions and complete questionnaires in English and/or Spanish.
  • Ability to understand and the willingness to sign a written informed consent document prior to any study-related procedures.
  • Willing to travel to DFCI for necessary data collection.

Exclusion Criteria:

  • Patients who are morbidly obese (BMI>40 kg/m2) or Anorexic (BMI<17 kg/m2).
  • Unstable comorbidities that contraindicate participation in exercise program compliance. Patients with unstable comorbidities may develop unexpected adverse events from exercise. For the purpose of patients' safety, as well as because part of this study involves remote, home-based exercise where close supervision is not possible, patients with unstable medical conditions are excluded. Study staff will identify untreated or unmanaged conditions when screening and treating MDs must provide clearance prior to patient enrollment.
  • Patients with alcohol or drug abuse, significant mental or emotional problems that would interfere with compliance (assessed by NCCN Distress Thermometer).
  • Patients scheduled to receive single modality cancer treatment (unimodal therapy), scheduled surgery within 2 weeks of the pre-treatment clinic visit, or for whom treatment has already started.
  • Patients who are pregnant, or plan to become pregnant during study duration will be excluded due to the unknown nature of exercise on developing fetuses.
  • Subjects who in the opinion of the investigator may not be able to comply with the safety monitoring requirements of the study.

Study Design

Enrollment

20 participants

Anticipated

Intervention Model

Single group

Primary purpose

Supportive Care

Interventions and Outcome Measures

Arms

experimental: PERCC

Receives personalized virtual exercise program (aerobic and resistance exercise) 1x weekly for patients with lung cancer who plan on receiving neoadjuvant treatment followed by surgery.

Interventions

PERCC

Personalized at-home exercise program, including aerobic and resistance exercise. Supervised by trained exercise professional via ZOOM (HIPPA complaint video conferencing platform).

Study equipment of Fitbit and resistance bands will be provided to participants.

Primary outcome measure

  • Attendance of Exercise Sessions (Feasibility) [ Time Frame: From first exercise session to final exercise session (up to 24 weeks) ]

Central Contacts and Locations

Central contacts

Christina Dieli-Conwright, PhD, MPH

617-582-8321christinam_dieli-conwright@dfci.harvard.edu

Locations

Dana-Farber Cancer Institute

Recruiting

Boston, Massachusetts, United States, 02215

Contacts

Christina Dieli-Conwright

617-632-3800ChristinaM_Dieli-Conwright@dfci.harvard.edu

More Information

Sponsor

Dana-Farber Cancer Institute

Last update posted

Aug 5, 2026

Last verified

Feb, 2026

Keywords

  • Stage II Lung Cancer
  • Lung Cancer
  • Non-small Cell Lung Cancer
  • NSCLC

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Dana-Farber Cancer Institute on 2026-08-05.